-
Epiprobe Biotech was invited to participate in ...
In the golden autumn of September, global attention once again turned to Fushan Bay, where the All-China Women's Federation, the SCO Cooperation Committee, the Shandong Provincial Government, and the SCO Secretariat co-hosted this significant event. The forum took place ...Read more -
Over 60,000 cases were registered for participa...
Over 60,000 cases were registered for participation! Epiprobe Biotech 100,000-case large-scale public welfare scientific research project for the prevention of cervical cancer has entered the follow-up stage ...Read more -
Congratulations! Epiprobe Biotech Wins Two R...
Recently, the 3rd ZAODX World Cancer Early Detection Conference was successfully held at the Xiongan Exhibition Center in Xiongan New Area, Hebei Province. This year's conference, with the theme of "Early Detection of Cancer, Standardized Action," covered multiple discip...Read more -
Epiprobe Biotech’s early detection produc...
On April 20, 2024, The Expert Consensus on Detection and Clinical Application of Tumor DNA Methylation Markers (hereinafter referred to as "Consensus"), which was condensed by the Expert Committee of Tumor Markers Professional Comm...Read more -
Epiprobe company won the title of “Specia...
Recently, Shanghai Municipal Commission of Economy and Information Technology announced the list of Shanghai small and medium-sized enterprises which are specialization, refinement, distinctiveness and novelty (second batch) in 2022. Shanghai Epiprobe Biotechnology Co., Ltd. relies on its experti...Read more -
The Urothelial Cancer Detection Kit was recogni...
Early May 2023, TAGMe DNA Methylation Detection Kit(qPCR) for Urothelial Cancer independently developed by Shanghai Epiprobe Biotechnology Co., Ltd, obtained “Breakthrough Device Designation” from US FDA. US FDA Breakthrough Devices Program aims to ensure promoting the a...Read more -
TAGMe DNA Methylation Detection Kits (qPCR) for...
Solution for endometrial cancer, eliminating cancer at the stage of precancerous lesions. Endometrial cancer is one of the three major malignant cancers in gynecology. Endometrial cancer is one of the most common malignant cancers in the female reproductive system, ranki...Read more -
Baidu Health and Epiprobe cooperatively advance...
Oct. 30, 2022, Baidu Health Internet Hospital (referred as "Baidu Health") and Shanghai Epiprobe Biotechnology Co., Ltd. (referred as "Epiprobe") has announced strategic cooperation to popularize the early pan-cancer screening in clinical and general health channels duri...Read more -
Epiprobe’s three cancer methylation detection k...
On May 8, 2022, Epiprobe announced that its independently developed three cancer gene methylation detection kits: TAGMe DNA Methylation Detection Kits (qPCR) for Cervical Cancer, TAGMe DNA Methylation Detection Kits (qPCR) for End...Read more -
Epiprobe completed nearly RMB 100 million of Se...
In recent, Shanghai Epiprobe Biotechnology Co., Ltd. (refer as "Epiprobe") announced that it had completed nearly RMB 100 million in Series B financing, which is jointly invested by industrial capital, government investment platfor...Read more
